Retinal Degeneration - Pipeline Review, H2 2015 Is Released Retinal Degeneration - Pipeline Review, H2 2015 Summary Global Markets Direct s, Retinal Degeneration - Pipeline Review, H2 2015, provides an overview of the Retinal Degenerations therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Retinal Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Degeneration and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Retinal Degeneration - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Retinal Degeneration and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Retinal Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Retinal Degeneration pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Retinal Degeneration - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Retinal Degeneration pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance
1
and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Browse with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173383/retinaldegeneration-pipeline-review-h2-2015 To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173383/retinal-degeneration-pipeline-review-h2-2015 Table of Contents
ntroduction 8 Global Markets Direct Report Coverage 8 Retinal Degeneration Overview 9 Therapeutics Development 10 Pipeline Products for Retinal Degeneration - Overview 10 Pipeline Products for Retinal Degeneration - Comparative Analysis 11 Retinal Degeneration - Therapeutics under Development by Companies 12 Retinal Degeneration - Therapeutics under Investigation by Universities/Institutes 13 Retinal Degeneration - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Retinal Degeneration - Products under Development by Companies 18 Retinal Degeneration - Products under Investigation by Universities/Institutes 19 Retinal Degeneration - Companies Involved in Therapeutics Development 20 2-BBB Medicines BV 20 Alkeus Pharmaceuticals, Inc. 21 Applied Genetic Technologies Corporation 22 Bionature E.A. Ltd. 23 2
Biovista Inc. 24 GenSight Biologics SA 25 SanBio, Inc. 26 Santhera Pharmaceuticals Holding AG 27 Senju Pharmaceutical Co., Ltd. 28 Retinal Degeneration - Therapeutics Assessment 29 Assessment by Monotherapy Products 29 Assessment by Target 30 Assessment by Mechanism of Action 32 Assessment by Route of Administration 34 Assessment by Molecule Type 36 Drug Profiles 38 BVA-202 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 BVA-203 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 CB-11 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 CNS-102 - Drug Profile 41 Product Description 41 Mechanism of Action 41 3
R&D Progress 41 Drug for Lebers Hereditary Optic Neuropathy - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Gene Therapy for X-linked retinoschisis - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Gene Therapy to Activate ND4 for Leber's Hereditary Optic Neuropathy - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Gene Therapy to Activate Retinoschisin for X-Linked Retinoschisis - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 GS-010 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 GS-011 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 idebenone - Drug Profile 49
4
Product Description 49 Mechanism of Action 49 R&D Progress 49 KH-176 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 MTP-131 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 SB-623 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Small Molecules for Inherited Retinal Diseases - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Small Molecules to Agonize Neurotrophin Receptor for CNS and Ophthalmological Disorders - Drug Profile 59 Product Description 59 Mechanism of Action 59 5
R&D Progress 59 SNJ-1945 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Stem Cell Therapy for Cancer, Pain, Retinal Degeneration and Niemann-Pick Disease - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Retinal Degeneration - Recent Pipeline Updates 62 Retinal Degeneration - Dormant Projects 74 Retinal Degeneration - Product Development Milestones 75 Featured News & Press Releases 75 Jun 26, 2015: CHMP recommends granting a marketing authorization for Santhera's Raxone for the treatment of Leber's Hereditary Optic Neuropathy 75 Jun 05, 2014: European Medicines Agency Validates Santhera s Marketing Authorization Application for Raxone in Lebers Hereditary Optic Neuropathy 75 May 07, 2014: Santhera Files Marketing Authorization Application in European Union for Raxone in the Treatment of LHON 76 Mar 04, 2014: Santhera Presents New Efficacy Data from an Expanded Access Program with Raxone for the Treatment of Leber's Hereditary Optic Neuropathy 77 Jan 21, 2014: Temporary Authorization for Use Granted for Santhera's Raxone for the Treatment of Leber's Hereditary Optic Neuropathy in France 78 Jul 11, 2013: Santhera Initiates Collaboration with the European Vision Institute Clinical Research Network in LHON 79 Mar 22, 2013: Santhera Pharma Withdraws Marketing Authorization Application for Raxone In LHON 79 Jan 18, 2013: Santhera Pharma Receives Negative Opinion from EMA's CHMP On Marketing Authorization Application For Raxone 80 Nov 16, 2012: Santhera Pharma Expects CHMP Opinion on MAA for Raxone In Early 2013 81
6
Jul 26, 2011: Catena Improves Sight for Patients With Inherited Blindness, Newcastle University Study Finds 81 Appendix 83 Methodology 83 Coverage 83 Secondary Research 83 Primary Research 83 Expert Panel Validation 83 Contact Us 83 Disclaimer 84
Read More http://www.idatainsights.com/reports-landing-page.php?id=173383/retinaldegeneration-pipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects
7
8